Wednesday 14 October 2026
Afternoon Edition
ZOTPAPER

News without the noise

ZOTPAPER
Science

Melbourne launches world-first trial to find best caffeine dose for premature babies

BabyCCINO study will compare three dosing regimens across about 4,000 infants in Australia, New Zealand and the UK

By LineZotpaper
Published
Read Time2 min
A world-first international trial launching in Melbourne will test three caffeine dosing regimens on about 4,000 premature babies in Australia, New Zealand and the United Kingdom, in a bid to determine the safest and most effective way to use the drug in neonatal care.

Named BabyCCINO, the study is being led from Mercy Hospital for Women in Melbourne. It comes as researchers acknowledge that while caffeine has helped premature babies breathe for decades, the ideal dose remains unknown.

Among the babies already receiving caffeine is Nellie, born at 23 weeks and six days and cared for at Mercy. Her mother, Amy Giles, described the experience as daunting. "We were obviously quite uncertain as to what was going to happen," she said, adding that recent weeks had brought "a lot more good days than bad days."

Professor Brett Manley, from Mercy Hospital for Women and the University of Melbourne, said caffeine works by stimulating the brains of preterm infants "to remind them to breathe." Pauses in breathing can cause oxygen levels to drop, sometimes requiring help from clinicians.

Manley said researchers believe higher doses than those used routinely could work better, "but we need to prove that in a big clinical trial so we make sure that our babies get the safest and most effective treatment."

Neonatal consultant Dr Katie Van Schilfgaarde said the benefits extended beyond intensive care. "Babies who are given caffeine do better in the long term after they leave the nursery."

The researchers will examine babies' health in hospital and then assess their growth and development two to three years later. Manley described the study as "the largest trial of caffeine dosing in very preterm babies ever done." The findings could shape treatment guidelines worldwide, with participating intensive care units expected to implement results immediately.

"Straight away, the babies that are in those units will receive the best dose of caffeine," Manley said.

For Giles, the next milestone is clear. "I'm most looking forward to getting Nellie home and having the family back together."

§

Analysis

Why This Matters

  • Caffeine is a standard treatment for pauses in breathing in preterm babies, but the optimal dose has never been settled. A clearer answer could improve both short-term breathing support and long-term outcomes for the most vulnerable newborns.
  • The trial's size and international scope mean its findings are likely to shape neonatal treatment guidelines well beyond Australia.
  • About 4,000 families are directly affected, and participating units plan to adopt the results immediately after the study concludes.

Background

Caffeine has been used for decades to help premature babies breathe, acting on the brain to stimulate breathing when pauses cause oxygen levels to drop. Routine dosing has been in use for many years, but researchers believe higher doses could achieve better results. The BabyCCINO trial is designed to test that question rigorously. Health checks during the hospital stay will be followed by assessments of growth and development two to three years later, giving the study a long-term view of each dosing regimen.

Key Perspectives

Researchers and clinicians: Led by Professor Brett Manley, the team argues the trial is needed to prove whether higher doses are both safer and more effective before changing practice. Dr Katie Van Schilfgaarde points to evidence that caffeine improves long-term outcomes for babies after they leave the nursery.

Participating neonatal units: Hospitals across Australia, New Zealand and the UK are expected to implement the results straight away, meaning the trial's findings will flow quickly into everyday care.

Critics and skeptics: The trial is a response to uncertainty rather than an attack on current practice. Larger caffeine doses bring a responsibility to confirm safety as well as benefit, which is why growth and development will be tracked for years after discharge.

What to Watch

  • The pace of recruitment for about 4,000 babies across three countries.
  • The two to three year follow-up results, which will determine whether higher doses improve longer-term development.
  • Whether treatment guidelines in participating countries are updated as the trial's findings are published.

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workSubscribe